Voyager Therapeutics, Inc. (FRA:VT6)

Market Cap	95.74M -58.0%
Revenue (ttm)	30.16M -19.1%
Net Income	-94.29M
EPS	-1.62
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	1.576
Previous Close	1.690
Day's Range	1.576 - 1.576
52-Week Range	1.576 - 4.378
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small mo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VT6

Financial Performance

In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error